低分子肝素钙联合血脂康治疗不稳定型心绞痛的临床疗效观察  

Clinical study of low molecular weight heparin and xuezhikang on patients with unstable angina pectoris

作　　者：郝金红[1] 

机构地区：[1]齐齐哈尔医学院第一附属医院心内科,161041

出　　处：《中国实用医药》2009年第19期17-18,共2页China Practical Medicine

摘　　要：目的观察低分子肝素钙联用血脂康胶囊治疗不稳定型心绞痛(UAP)的临床疗效。方法不稳定型心绞痛患者88例随机分为对照组(45例),均采用常规治疗;观察组(43例)给予低分子肝素钙7500IU12h1次皮下注射,连用7d,合用血脂康胶囊,2粒,2次/d口服,连用14d。观察心脏事件发生以及服药前后血脂、纤维蛋白原(FIB)、外周血白细胞(WBC)的变化。结果观察组无一例进展为急性心肌梗死或死亡,未发现严重出血现象及其它副作用,总有效率92.6%;对照组3例进展为急性心肌梗死(AMI),总有效率70.4%,两组比较差异有显著性。结论低分子肝素钙联用血脂康治疗不稳定型心绞痛可减少不稳定型心绞痛复发性缺血事件发生,安全有效。Objective To observe the clinical effect and side-effect of low molecular weight heparin （LMWH） and xuezhikang on patients with unstable angina pectoris. Methods 88 patients with unstable angina pectoris were divided into LMWH group （n = 43 ）and control group（ n = 45 ） randomly. The two groups were given traditional therapy as usual, and LMWH group received additional LMWH（7500 IU per 12 h for 7 days by hypodermic injection）and xuezhikang （two capsulars was taken q12 h for 14 days）. The levels of blood lipid, white blood cell（WBC） and fibrinogen （FIB） were measured before and after treatment. Cardiac events were recorded after admission. Results There was no acute myocardial infarction or death in LMWH group. Total effective rate was 92. 6%. But in control group,3 cases developed into acute myocardial infarction. Total effective rate was 70. 4%. The difference of Lipid, WBC and FIB between two groups was significant. Conclusion LMWH and xuezhikang combined can reduce the recurrent ischemic events in the UAP significantly. It is an effective and safe method.

关 键 词：不稳定型心绞痛 低分子肝素钙 血脂康 

分 类 号：R541.4[医药卫生—心血管疾病] R259.892[医药卫生—内科学]